CMS Pays AI MORE Than Human Interpretation for Diabetic Retinopathy Screening — CPT 92229 = $40.28 (2024) vs 92228 = $29.14
CMS deliberately reimburses autonomous AI more than human interpretation for diabetic retinopathy screening. CPT 92229 (autonomous AI imaging) = $40.28 (2024); CPT 92228 (MD interpretation) = $29.14; CPT 92227 (staff review) = $17.35.
The price differential is intentional policy: CMS uses reimbursement to drive autonomous AI adoption in primary care settings — the policy tailwind for FQHCs is real. Combined with $40.28 reimbursement vs ~$15-25K refurbished Topcon NW400 fundus camera, AI DR screening can pay for the equipment quickly for an FQHC with a Type 2 diabetes panel.
Plus HEDIS EED quality measure improvement (only 64.8% of US diabetics get annual exam vs HP2030 70.3% target). One of the clearest vision technology scenarios for FQHCs to evaluate before deciding whether to adopt at scale.
Primary source
CMS / EyenukSource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
FQHC Talent. (2025, January 1). CMS Pays AI MORE Than Human Interpretation for Diabetic Retinopathy Screening — CPT 92229 = $40.28 (2024) vs 92228 = $29.14. Primary source: CMS / Eyenuk. Retrieved July 30, 2026, from https://www.fqhctalent.com/intel/cms-cpt-92229-autonomous-ai-reimbursement-2025
More in Funding & Budget
Dec 31
CalAIM Section 1115 Waiver Expires December 2026 — $1.2B/Year at Stake
Jul 21
CMS defers $867.5M in federal Medicaid funds from California DHCS, with a July 31 documentation deadline on the largest line
Jul 21
D.C. Circuit: drug makers can't force a 340B rebate model without HHS approval — the Secretary, not manufacturers, controls the program
Jul 21
Samuel Dixon Family Health Center wins $655K in state funding to erase the mortgage on its Newhall behavioral-health clinic